What is it about?
Mesenchymal stem cells (MSCs) curative effects onmethotrexate (MTX)-induced kidney and liver injuries remain elusive. Therefore, rats were divided into five groups, rats received MTX orally (14 mg/kg) as a single dose/week for 2 weeks, groups 3 and 4 were injected once with 2 × 106 cells bone marrow MSCs and adipose-derived MSCs, respectively. The last group administered dexamethasone (DEX) (0.5 mg/kg, p.o) for 7 days. MTX caused marked increase in malondialdehyde and nitrite/nitrate concentrations. However, MTX administration decreased reduced glutathione content plus catalase activity. In addition, MTX caused a significant increment in kidney and liver biomarkers levels.Moreover,MTXshowed renal tubules vacuolation and necrosis of hepatocytes, as well expression of caspase-3 and nuclear factor kappa beta in kidney and liver tissues were observed. MSCs treatment alleviated previous side effects induced by MTX. MSCs improved nephrotoxicity and hepatotoxicity induced by MTX to a better extent as compared with DEX.
Featured Image
Why is it important?
Our findings show MSCs exert their curative effects to guard against MTX-induced renal and liver damages via their antioxidant, anti-nitroactive stress, and anti-apoptotic potentials
Perspectives
Writing this article was a great pleasure as it has co-authors with whom I have had long standing collaborations.
Amany Gad
Read the Original
This page is a summary of: Significant curative functions of the mesenchymal stem cells on methotrexate-induced kidney and liver injuries in rats, Journal of Biochemical and Molecular Toxicology, April 2017, Wiley,
DOI: 10.1002/jbt.21919.
You can read the full text:
Contributors
The following have contributed to this page
